Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Viela Bio stock (VIE)

Buy Viela Bio stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Viela Bio is a biotechnology business based in the US. Viela Bio shares (VIE) are listed on the NASDAQ and all prices are listed in US Dollars. Viela Bio employs 170 staff and has a trailing 12-month revenue of around $11.7 million.

Our top picks for where to buy Viela Bio stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy Viela Bio stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – VIE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Viela Bio stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Product USFST Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Finder score
Stocks, ETFs
$0
$0
N/A
Earn up to $300
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Viela Bio stock price (NASDAQ: VIE)

Use our graph to track the performance of VIE stocks over time.

Viela Bio shares at a glance

Information last updated 2023-12-12.
52-week range$0.00 - $0.00
50-day moving average $53.07
200-day moving average $39.12
Wall St. target price$53.00
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-78.90

Is it a good time to buy Viela Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viela Bio financials

Revenue TTM $11.7 million
Gross profit TTM $9.6 million
Return on assets TTM -23.83%
Return on equity TTM -41.26%
Profit margin 0%
Book value $-293.22
Market Capitalization $2.9 billion

TTM: trailing 12 months

Viela Bio share dividends

We're not expecting Viela Bio to pay a dividend over the next 12 months.

Viela Bio overview

Viela Bio, Inc. , a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as in Phase II trial for kidney transplant desensitization. It is also developing VIB4920 that is in Phase II trial for kidney transplantation rejection and rheumatoid arthritis, as well as in Phase IIb trial for sjögren's syndrome; and VIB7734, which is in Phase Ib trial for cutaneous lupus erythematosus, in Phase I trial for COVID-19-related acute lung injury, and a planned Phase II tria for systemic lupus erythematosus. The company's pre-clinical research and development product candidates include VIB1116 to decrease the number and function of antigen-presenting dendritic cells; and a mAb cytokine fusion protein to inhibit inflammatory responses. Viela Bio, Inc. has a strategic collaboration with Hansoh Pharmaceutical Group Company Limited and Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in China, Hong Kong, Macau, Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan.

Frequently asked questions

What percentage of Viela Bio is owned by insiders or institutions?
Currently 55.079% of Viela Bio shares are held by insiders and 47.165% by institutions.
How many people work for Viela Bio?
Latest data suggests 170 work at Viela Bio.
When does the fiscal year end for Viela Bio?
Viela Bio's fiscal year ends in December.
Where is Viela Bio based?
Viela Bio's address is: One MedImmune Way, Gaithersburg, MD, United States, 20878
What is Viela Bio's ISIN number?
Viela Bio's international securities identification number is: US9266131005
What is Viela Bio's CUSIP number?
Viela Bio's Committee on Uniform Securities Identification Procedures number is: 926613100

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site